On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Mark R. Litzow, MD, and William A. Wood, MD.

Question Title

* 1. Which of the following statements about mechanism of action of granulocyte colony-stimulating factor (G-CSF) is CORRECT?

Question Title

* 2. AETHERA trial5 aimed to assess whether brentuximab vedotin improves progression free survival when given as early consolidation after autologous hematopoietic cell transplantation in subjects (age ≥18 years) with high-risk relapsed and primary refractory classic Hodgkin's lymphoma.

Which of the following statements is CORRECT?

Question Title

* 3. Which statement about autologous transplant and post-transplant consolidation therapy in classic Hodgkin’s lymphoma is CORRECT?

Question Title

* 4. Which of the following reflects distinct long-term hematopoietic stem cell phenotypic signature (flow cytometry-based characterization)

Question Title

* 5. Which statement about overall utilization of unrelated donors in pediatric allogeneic transplants is CORRECT?

T